NOVO-B Stock Analysis: Novo Nordisk | CO
Drug Manufacturers - General | CO, Denmark | Market Cap: 1.243.853m DKK | 12M Return: -26.6% | DK0062498333 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.32B
EPS Trend: 85.3%
Qual. Beats: 2
Rev. Trend: 96.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 and headquartered in Bagsvaerd, Denmark. It operates through two business segments: Obesity and Diabetes Care, which focuses on diabetes, obesity, cardiovascular, and emerging therapy areas; and Rare Disease, which addresses rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
The companys product portfolio includes smart insulin pens (NovoPen 6 and NovoPen Echo Plus), the Dose Check insulin dose guidance application, growth hormone pens, injection needles, and Wegovy, an oral GLP-1 receptor agonist therapy for weight management. Novo Nordisk distributes its products globally across Europe, North America, Asia, Latin America, the Middle East, and Africa.
As a large-cap biotechnology company in the healthcare sector, Novo Nordisks business model is centered on the research, development, manufacture, and distribution of prescription pharmaceuticals, with revenue heavily dependent on patented therapies in the GLP-1 drug class and rare disease treatments. The pharmaceutical industry is characterized by high R&D investment, long product development cycles, and reliance on regulatory approvals and intellectual property protection.
- Wegovy and Ozempic demand drives obesity segment growth
- Eli Lilly Zepbound competition pressures GLP-1 market share
- US Medicare pricing negotiations threaten diabetes margins
| Net Income: 116b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -4.63 > 1.0 |
| NWC/Revenue: -9.22% < 20% (prev -14.37%; Δ 5.14% < -1%) |
| CFO/TA 0.22 > 3% & CFO 133b > Net Income 116b |
| Net Debt (104b) to EBITDA (173b): 0.60 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.44b) vs 12m ago -0.25% < -2% |
| Gross Margin: 80.65% > 18% (prev 83.95%; Δ -3.30% > 0.5%) |
| Asset Turnover: 61.17% > 50% (prev 64.70%; Δ -3.53% > 0%) |
| Interest Coverage Ratio: 8.18 > 6 (EBIT TTM 150b / Interest Expense TTM 18.4b) |
| A: -0.05 (Total Current Assets 209b - Total Current Liabilities 239b) / Total Assets 595b |
| B: 0.38 (Retained Earnings 224b / Total Assets 595b) |
| C: 0.28 (EBIT TTM 150b / Avg Total Assets 539b) |
| D: 0.59 (Book Value of Equity 221b / Total Liabilities 374b) |
| Altman-Z'' = 3.39 = A |
| DSRI: 1.20 (Receivables 109b/85.8b, Revenue 329b/312b) |
| GMI: 1.04 (GM 83.95% / 80.65%) |
| AQI: 0.90 (AQ_t 0.26 / AQ_t-1 0.29) |
| SGI: 1.06 (Revenue 329b / 312b) |
| TATA: -0.03 (NI 116b - CFO 133b) / TA 595b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at DKK 253.00 with a total of 3,906,196 shares traded. Over the past week, the price has changed by -10.14%, over one month by -17.80%, over three months by -18.83% and over the past year by -26.60%.
Current recommended Stop Loss: 237.60 (which is 6.1% or 1.8 ATR below the current price).
Novo Nordisk has no consensus analysts rating.
P/E Trailing = 10.7298
P/E Forward = 13.2275
P/S = 3.7758
P/B = 5.5773
P/EG = 3.0681
Revenue TTM = 329b DKK
EBIT TTM = 150b DKK
EBITDA TTM = 173b DKK
Long Term Debt = 122b DKK (from longTermDebt, last quarter)
Short Term Debt = 18.3b DKK (from shortTermDebt, last quarter)
Debt = 149b DKK (from shortLongTermDebtTotal, last quarter) + Leases 8.57b
Net Debt = 104b DKK (calculated: Debt 149b - CCE 45.0b)
Enterprise Value = 1348b DKK (1244b + Debt 149b - CCE 45.0b)
Interest Coverage Ratio = 8.18 (Ebit TTM 150b / Interest Expense TTM 18.4b)
EV/FCF = 27.55x (Enterprise Value 1348b / FCF TTM 48.9b)
FCF Yield = 3.63% (FCF TTM 48.9b / Enterprise Value 1348b)
FCF Margin = 14.85% (FCF TTM 48.9b / Revenue TTM 329b)
Net Margin = 35.35% (Net Income TTM 116b / Revenue TTM 329b)
Gross Margin = 80.65% ((Revenue TTM 329b - Cost of Revenue TTM 63.8b) / Revenue TTM)
Gross Margin QoQ = 78.21% (prev 85.96%)
Tobins Q-Ratio = 2.27 (Enterprise Value 1348b / Total Assets 595b)
Interest Expense / Debt = 12.36% (Interest Expense 18.4b / Debt 149b)
Taxrate = 21.72% (32.3b / 149b)
NOPAT = 118b (EBIT 150b * (1 - 21.72%))
Current Ratio = 0.87 (Total Current Assets 209b / Total Current Liabilities 239b)
Debt / Equity = 0.67 (Debt 149b / totalStockholderEquity, last quarter 221b)
Debt / EBITDA = 0.60 (Net Debt 104b / EBITDA 173b)
Debt / FCF = 2.12 (Net Debt 104b / FCF TTM 48.9b)
Total Stockholder Equity = 197b (last 4 quarters mean from totalStockholderEquity)
RoA = 21.62% (Net Income 116b / Total Assets 595b)
RoE = 59.09% (Net Income TTM 116b / Total Stockholder Equity 197b)
RoCE = 47.16% (EBIT 150b / Capital Employed (Equity 197b + L.T.Debt 122b))
RoIC = 32.91% (NOPAT 118b / Invested Capital 358b)
WACC = 7.88% (E(1244b)/V(1393b) * Re(7.66%) + D(149b)/V(1393b) * Rd(12.36%) * (1-Tc(0.22)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -89.98 | Cagr: -0.35%
[DCF] Terminal Value 73.10% ; FCFF base≈54.1b ; Y1≈47.5b ; Y5≈38.4b
[DCF] Fair Price = 153.2 (EV 616b - Net Debt 104b = Equity 512b / Shares 3.34b; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 85.33 | EPS CAGR: 11.71% | SUE: 2.09 | # QB: 2
Revenue Correlation: 96.08 | Revenue CAGR: 16.54% | SUE: 0.76 | # QB: 0
EPS current Quarter (2026-09-30): EPS=5.11 | Chg30d=+2.09% | Revisions=+57% | Analysts=3
EPS current Year (2026-12-31): EPS=21.58 | Chg30d=+0.98% | Revisions=+61% | GrowthEPS=-6.3% | GrowthRev=-3.0%
EPS next Year (2027-12-31): EPS=21.81 | Chg30d=-0.49% | Revisions=+71% | GrowthEPS=+1.1% | GrowthRev=+1.3%
[Analyst] Revisions Ratio: +75% (up=30, down=3)